Eosinophilic Esophagitis - Pipeline Insight, 2024

Eosinophilic Esophagitis - Pipeline Insight, 2024

DelveInsight’s, “Eosinophilic Esophagitis - Pipeline Insight, 2024,” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Eosinophilic Esophagitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Eosinophilic Esophagitis: Understanding

Eosinophilic Esophagitis: Overview

Eosinophilic esophagitis (EoE) is a chronic disorder of the digestive system in which large numbers of a particular type of white blood cell called eosinophils are present in the esophagus. The esophagus is the tube that carries food from the mouth to the stomach. Eosinophils can be found in the esophagus in response to various stimuli or antigen. Eosinophilic esophagitis (EoE) is a chronic immune or antigen-mediated process. Clinically, it presents with various esophageal dysfunction, and pathologically, there is mucosal inflammation predominantly with eosinophils, which is confined to the esophagus only.

""Eosinophilic Esophagitis- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Eosinophilic Esophagitis pipeline landscape is provided which includes the disease overview and Eosinophilic Esophagitis treatment guidelines. The assessment part of the report embraces, in depth Eosinophilic Esophagitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Eosinophilic Esophagitis (EoE) occurs as a result of an immunogenic reaction to various antigens which are commonly found in food and air. There is a strong genetic component involved in the pathogenesis of EoE and a high concordance reported for EoE among family members. Study reported that the gene responsible for EoE was TSLP which is located in the 5q22 region of male X chromosome. TSLP stimulates Th2 cells and induces eotaxin-3. The stimulated Th2 cells activate various proinflammatory cytokines such as IL5, IL13, and IL15, which recruit eosinophils. Eotaxin-3 is overexpressed in the esophageal mucosa in EoE patients. Overall, this immunogenic process starts as an allergic response to various environmental antigens, food leads to the inflammation of esophageal mucosa. The other important cytokine involved in the pathogenesis is TGF-B, which is released by eosinophils and mast cells recruited after immune activation.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence in Eosinophilic Esophagitis R&D. The therapies under development are focused on novel approaches to treat/improve in Eosinophilic Esophagitis.

This segment of the Eosinophilic Esophagitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Eosinophilic Esophagitis Emerging Drugs

• APT-1011: Ellodi Pharmaceuticals.

APT-1011 is a novel, proprietary, once daily, investigational oral disintegrating tablet designed to deliver fluticasone propionate to the esophageal mucosa while minimizing residence time in the oral cavity. In earlier clinical trials, APT-1011 reduced esophageal eosinophil counts and endoscopic findings in adults with a diagnosis of EoE. It is currently in clinical development, following successful completion of FLUTE I and FLUTE II. It has been granted orphan drug status by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Currently the product is in Phase III stage of development for the treatment of Eosinophilic Esophagitis

Further product details are provided in the report……..

Eosinophilic Esophagitis: Therapeutic Assessment

This segment of the report provides insights about the different Eosinophilic Esophagitis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Eosinophilic Esophagitis

There are approx. 18+ key companies which are developing the therapies for Eosinophilic Esophagitis. The companies which have their Eosinophilic Esophagitis drug candidates in the most advanced stage, i.e. Phase III include, Ellodi Pharmaceuticals

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Eosinophilic Esophagitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Molecule Type

Products have been categorized under various Molecule types such as

• Peptide
• Protein
• Propylene glycols
• Cell Therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Eosinophilic Esophagitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Eosinophilic Esophagitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Eosinophilic Esophagitis drugs.

Eosinophilic Esophagitis Report Insights

• Eosinophilic Esophagitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Eosinophilic Esophagitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Eosinophilic Esophagitis drugs?
• How many Eosinophilic Esophagitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Eosinophilic Esophagitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Eosinophilic Esophagitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Eosinophilic Esophagitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AstraZeneca
• Bristol Myers Squibb
• Ellodi Pharmaceuticals
• Allakos
• EsoCap AG
• Arena Pharmaceuticals
• GlaxoSmithKline
• Landos Biopharma
• Calypso Biotech
• Takeda
• Dr Falk Pharma
• DBV Technologies
• Revolo Biotherapeutics
• EsoCap
• Aqilion
• Serpin Pharma

Key Products

• Benralizumab
• CC-93538
• APT-1011
• AK002
• ESO-101
• Etrasimod
• Mepolizumab
• CALY-002
• BT-11
• TAK-721
• Milk allergy immunotherapy
• IRL201104
• Mometasone
• AQ280
• SP 16